brivaracetam
Nervous system (N03)US regulatory status: approved. Molecular target: Synaptic vesicle glycoprotein 2A.
- Target
- Synaptic vesicle glycoprotein 2A
- Mechanism
- Synaptic vesicle glycoprotein 2A modulator
pharma · Epilepsy
Ucb Pharma S.P.A
UCB Pharma
Ucb Pharma S.P.A drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
ANDERLECHT, IT HQ
4 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- ANDERLECHT, IT
- Employees
- 4
- Programs
- 2
- Drugs
- 3
- Patents
- 0
Ucb Pharma S.P.A pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Ucb Pharma S.P.A drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
levetiracetam
Nervous system (N03)US regulatory status: approved. Molecular target: Synaptic vesicle glycoprotein 2A.
- Target
- Synaptic vesicle glycoprotein 2A
- Mechanism
- Synaptic vesicle glycoprotein 2A modulator
-
Development asset linked to Ucb Pharma S.P.A in public FDA and regional records.